Stockscreener 앱 받기
50.75
5.84%
2.6179
전일 마감가:
$48.13
열려 있는:
$48.13
하루 거래량:
841.53K
Relative Volume:
0.57
시가총액:
$6.09B
수익:
$47.30M
순이익/손실:
$-377.94M
주가수익비율:
-14.81
EPS:
-3.4256
순현금흐름:
$-300.64M
1주 성능:
+7.11%
1개월 성능:
+9.60%
6개월 성능:
+18.06%
1년 성능:
+69.80%
1일 변동 폭
$47.83
$51.30
1주일 범위
$46.30
$51.30
52주 변동 폭
$27.07
$51.62
Scholar Rock Holding Corp Stock (SRRK) Company Profile
명칭
Scholar Rock Holding Corp
전화
857-259-3860
주소
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
50.80 | 5.77B | 47.30M | -377.94M | -300.64M | -3.4256 |
VRTX
Vertex Pharmaceuticals Inc
|
436.11 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.73 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.68 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.75 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.51 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-01-09 | 개시 | Citigroup | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-09 | 개시 | BofA Securities | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 재개 | Jefferies | Buy |
| 2025-07-30 | 재개 | Raymond James | Strong Buy |
| 2025-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-26 | 재확인 | H.C. Wainwright | Buy |
| 2024-10-07 | 재확인 | H.C. Wainwright | Buy |
| 2024-03-28 | 개시 | Raymond James | Strong Buy |
| 2023-10-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Overweight |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-07-12 | 개시 | Truist | Buy |
| 2022-03-23 | 개시 | H.C. Wainwright | Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-03-12 | 개시 | Robert W. Baird | Outperform |
모두보기
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
SRRK Stock Price, Quote & Chart | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
103,191 Shares in Scholar Rock Holding Corporation $SRRK Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Biotech Scholar Rock to webcast Jefferies healthcare talk June 3 - Stock Titan
Three Biotechs That Are Top Takeover Targets - Yahoo Finance
iA Global Asset Management Inc. Makes New $5.43 Million Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Charles Schwab Investment Management Inc. Acquires 25,060 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Redmile Group owns 7.6% of Scholar Rock (SRRK) via funds and affiliates - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
T. Rowe Price holds 5.4% of Scholar Rock (NASDAQ: SRRK) - Stock Titan
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises - Investing.com Nigeria
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises By Investing.com - Investing.com South Africa
Transcript : Scholar Rock Holding Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
HC Wainwright Has Positive View of Scholar Rock Q2 Earnings - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After FDA Acceptance Of Apitegromab BLA - Sahm
State of New Jersey Common Pension Fund D Buys New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
TradingKey - TradingKey
Number of shareholders of Scholar Rock Holding Corp. – FWB:2QK - TradingView
FY2029 EPS Estimates for Scholar Rock Increased by Analyst - MarketBeat
Scholar Rock (SRRK) Q1 2026 Earnings Transcript - AOL.com
Nan Fung Trinity HK Ltd. Buys 225,603 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Vanguard Group Inc. Boosts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript - Insider Monkey
Scholar Rock Q1 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results - MarketBeat
SRRK Maintained by Barclays -- Price Target Raised to $55 - GuruFocus
Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites - MSN
Scholar Rock (SRRK) Receives Positive Catalyst Watch from JPMorg - GuruFocus
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $65 - GuruFocus
UBS Group AG Sells 226,355 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Transcript : Scholar Rock Holding Corporation, Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Scholar Rock Q1 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss By Investing.com - Investing.com South Africa
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss - Investing.com Nigeria
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches - TipRanks
Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.83 a Share, vs. FactSet Est of $0.80 Loss - marketscreener.com
Q1 2026 Scholar Rock Holding Corp Earnings Call Transcript - GuruFocus
Scholar Rock (NASDAQ: SRRK) details March 31 2026 quarter - Stock Titan
Scholar Rock (SRRK) boosts cash to $480M as FDA sets apitegromab PDUFA date - Stock Titan
Scholar Rock gets Sept. 30 FDA decision date for SMA drug - Stock Titan
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
MSN Money - MSN
Scholar Rock faces earnings test as apitegromab approval looms By Investing.com - Investing.com South Africa
Scholar Rock faces earnings test as apitegromab approval looms - Investing.com
Evercore ISI initiates Scholar Rock stock coverage with outperform rating By Investing.com - Investing.com Australia
Scholar Rock Holding Corp (SRRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):